Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Zimmer Biomet : Misses Analysts' 2Q Profit Estimates

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/26/2019 | 06:32am EDT

By Michael Tobin

Zimmer Biomet Holdings (ZBH) reported Friday that second-quarter profit fell, but the company raised its end of year adjusted earnings guidance.

The medical device company had $133.7 million in second-quarter net income, or 65 cents a share, compared with $185.0 million, or 90 cents a share, a year earlier. Analysts polled by FactSet estimated earnings of $1.19 a share.

Zimmer had $1.93 in adjusted earnings, compared with $1.92 during last year's second quarter. Analysts estimated adjusted earnings of $1.91.

Zimmer had $1.99 billion in revenue, compared with $2.01 billion a year earlier. Analysts were expecting $1.98 billion.

The company raised the lower end of its end of year adjusted diluted earnings per share to $7.75-$7.90, up from $7.70-$7.90.

Write to Michael Tobin at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS
07/26ZIMMER BIOMET : Recommends Shareholders Reject Mini-Tender Offer by TRC Capital ..
PR
07/26Health Care Up on Earnings -- Health Care Roundup
DJ
07/26ZIMMER BIOMET : Profit, Revenue Decline -- Update
DJ
07/26ZIMMER BIOMET : Misses Analysts' 2Q Profit Estimates
DJ
07/26ZIMMER BIOMET : Current report filing
PU
07/26ZIMMER : 2Q Earnings Snapshot
AQ
07/26ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
AQ
07/26ZIMMER BIOMET : Description Reconciliation of Gross Profit & Margin to Adjusted ..
PU
07/26ZIMMER BIOMET : Description Reconciliation of Operating Profit & Margin to Adjus..
PU
07/26ZIMMER BIOMET : Description Reconciliation of Cash Flow from Operating Activitie..
PU
More news
Financials (USD)
Sales 2019 7 953 M
EBIT 2019 2 181 M
Net income 2019 1 082 M
Debt 2019 7 342 M
Yield 2019 0,73%
P/E ratio 2019 27,1x
P/E ratio 2020 22,7x
EV / Sales2019 4,39x
EV / Sales2020 4,09x
Capitalization 27 545 M
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 141,00  $
Last Close Price 134,50  $
Spread / Highest target 26,4%
Spread / Average Target 4,83%
Spread / Lowest Target -24,9%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Daniel P. Florin EVP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS29.68%27 545
MEDTRONIC PLC12.24%137 536
BAXTER INTERNATIONAL INC.29.37%43 441
HOYA CORPORATION30.77%29 349
TERUMO CORP-47.98%21 615
ALIGN TECHNOLOGY-5.06%15 908